XML 21 R15.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE
9 Months Ended
Sep. 30, 2019
REVENUE  
REVENUE

9.  REVENUE

​

The following table disaggregates net sales by therapeutic categories for the Specialty segment and by product and service distribution channels for the PBM segment:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

​

September 30, 

​

September 30, 

​

​

    

2019

    

2018

    

2019

    

2018

​

Specialty Segment:

​

​

​

​

​

​

​

​

​

​

​

​

​

Oncology

​

$

718,859

​

$

701,206

​

$

2,123,574

​

$

2,094,394

​

Specialty infusion

​

 

209,767

​

 

178,890

​

 

580,254

​

 

525,857

​

Immunology

​

 

135,740

​

 

135,397

​

 

412,268

​

 

413,948

​

Other

​

 

179,082

​

 

196,805

​

 

511,486

​

 

564,824

​

Total Specialty segment

​

​

1,243,448

​

​

1,212,298

​

​

3,627,582

​

​

3,599,023

​

PBM Segment:

​

​

​

​

​

​

​

​

​

​

​

​

​

Retail networks

​

​

48,604

​

​

126,082

​

​

173,800

​

​

417,370

​

Specialty pharmacy

​

​

23,156

​

​

22,470

​

​

57,323

​

​

67,784

​

Mail order

​

​

7,976

​

​

16,019

​

​

30,758

​

​

50,029

​

Other

​

​

2,764

​

​

5,362

​

​

8,849

​

​

14,965

​

Total PBM segment

​

​

82,500

​

​

169,933

​

​

270,730

​

​

550,148

​

Inter-segment eliminations

​

​

(24,751)

​

​

(8,897)

​

​

(52,683)

​

​

(17,275)

​

Total net sales

​

$

1,301,197

​

$

1,373,334

​

$

3,845,629

​

$

4,131,896

​

​

Rebates retained, which represents the difference between the manufacturers’ rebates earned and rebates incurred to customers, approximated (5.5%) and 22.1% of total gross profit for the three months ended September 30, 2019 and 2018,

respectively and 5.9% and 17.2% of total gross profit for the nine months ended September 30, 2019 and 2018, respectively.

​

Rebates retained was negatively impacted for the three and nine months ended September 30, 2019.  In the third quarter of 2019, manufacturers’ rebates earned, recorded in Cost of sales, includes an approximate $9,000 adjustment due to the Company’s inability to meet certain contractual membership level requirements in 2019, as included in the PBM aggregator’s contract, necessary to maintain contractual rebate rates.  The Company had met the membership requirements for this standard contract for the years 2017 and 2018.  At the end of the second quarter of 2019, the Company was in negotiations with the aggregator, as required by the contract, regarding contract renewals (including the potential for adjustments to rebate pricing in the future and retroactively to January 1, 2019). In late August 2019, negotiations concluded with the aggregator assessing a rebate penalty of approximately $9,000 of which approximately $6,000 related to the six months ended June 30, 2019.  The aggregator began withholding from monthly rebate payments in September and October of 2019 to recover the penalty amount.  

​

Additionally, as of September 30, 2019, the Company recorded against Net sales, the recognition of an accrual for litigation of $3,900 relating to a rebate dispute with a terminated customer.